Hydrochlorothiazide and Prevention of Kidney-Stone RecurrenceNasser A. Dhayat, Daniel G. Fuster, Giulia Bedino et al.|New England Journal of Medicine|2023Cited by 128
Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trialNasser A. Dhayat, Daniel G. Fuster, Nicolas Faller et al.|BMC Nephrology|2018Cited by 33
The Vitamin D Metabolite Diagnostic Ratio Associates With Phenotypic Traits of Idiopathic HypercalciuriaNasser A. Dhayat, Daniel G. Fuster, Cédric Mattmann et al.|Kidney International Reports|2024Cited by 7
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney StonesAndreas Christe, Daniel G. Fuster, Elias Primetis et al.|Clinical Journal of the American Society of Nephrology|2025Cited by 1